Added Benefit For Orphans Is ‘Fictitious’ Says German HTA Body
Executive Summary
Industry has warned that reforming the system for evaluating orphan drugs could have serious consequences for patient access.
You may also be interested in...
Alnylam's Amvuttra Tests Faster HTA In England, Wins Praise in Germany For Full Assessment
Alnylam has opted to submit its orphan drug Amvuttra for a full benefit assessment in Germany, rather than an abbreviated process that requires no comparative data. In England, the drug was recommended following a pilot for designing a new and faster approach to health technology appraisals.
Germany’s New Government Will Maintain Price Freeze And Slash Free Pricing Period
Big changes are in store on the drug pricing front in Germany. Further reforms could depend on who is appointed health minister.
Proposals On EU-Wide Joint Clinical Assessments Fall Short, Warn German Industry Groups
The German pharmaceutical industry is calling for “directional correction” to the way implementation of the EU’s Health Technology Assessment Regulation is being developed.